Medicine Recommendations

Treatment of schizophrenia in adult patients 

Pain: Anti-inflammatory

Treating focal onset seizures in epilepsy (NICE TA753)

NICE TA753 - Cenobamate for treating focal onset seizures in epilepsy

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Alcohol withdrawal

Anxiety

Schizophrenia and other psychoses, mania, anxiety, agitation, violent or dangerously impulsive behaviour, childhood schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia and other psychoses, mania, anxiety, agitation, violent or dangerously impulsive behaviour, childhood schizophrenia

Depressive illness, panic disorder

MHRA Drug Safety Update - Citalopram and escitalopram: QT interval prolongation

Adjunct in epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Depressive illness, phobic and obsessional states

Depressive illness, phobic and obsessional states

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

All forms of epilepsy

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products   

Anxiety (off label use)

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

Mood Disorders

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

ADHD

Tourette syndrome (unlicensed indication)

Treatment resistant/intolerant Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Parkinson's disease

Pain